MRP1 mediates folate transport and antifolate sensitivity in Plasmodium falciparum

Sanna R Rijpma1, Maarten van der Velden1, Albert Bilos1

  • 1Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands.

FEBS Letters
|February 23, 2016
PubMed

Insights

Multidrug resistance-associated proteins (MRP) in Plasmodium falciparum export folate, impacting drug sensitivity. Lack of MRP1 reduces folate levels and sensitivity to antifolates like methotrexate, crucial for malaria treatment.

Area of Science:

  • Parasitology
  • Molecular Biology
  • Drug Resistance

Background:

  • Multidrug resistance-associated proteins (MRP) in Plasmodium falciparum are linked to altered drug sensitivity.
  • Understanding MRP substrate specificity is key to characterizing resistance mechanisms and parasite physiology.

Purpose of the Study:

  • To investigate the role of Plasmodium falciparum MRP1 in folate transport and its impact on drug sensitivity.
  • To elucidate the physiological functions of MRPs in malaria parasites.

Main Methods:

  • Untargeted metabolomics approach.
  • Analysis of red blood cells infected with schizont stage parasites lacking MRP1 expression.
  • Drug sensitivity testing using the folate analog methotrexate.

Main Results:

  • Decreased folate concentrations were detected in red blood cells infected with parasites lacking MRP1.
  • Parasites lacking MRP1 exhibited a tenfold decrease in sensitivity to methotrexate.
  • PfMRP1 facilitates the export of folate from parasites into red blood cells.

Conclusions:

  • PfMRP1 plays a significant role in folate homeostasis within malaria parasites.
  • PfMRP1 is a critical factor for parasite sensitivity to antifolate drugs.
  • Targeting PfMRP1 or the folate pathway could be a viable strategy for malaria treatment.

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
111
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
60
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.5K